Systemic lupus erythematosus (SLE) is an autoimmune disease with protean manifestations
that predominantly affects young women. Certain ethnic groups are more vulnerable than …

Clinical heterogeneity, unpredictable course and flares are characteristics of systemic lupus
erythematosus (SLE). Although SLE is—by and large—a systemic disease, occasionally it …

Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease. Knowledge
of circulating immune cell types and states associated with SLE remains incomplete. We …

Objectives To quantify global, regional and country-specific estimates of epidemiology of
systemic lupus erythematosus (SLE). Methods Four databases were systematically …

In humans, a complex interaction between the host immune system and commensal
microbiota is required to maintain gut homeostasis. In this symbiotic relationship, the …

Objective Systemic lupus erythematosus (SLE), an autoimmune disorder, has been
associated with nearly 100 susceptibility loci. Nevertheless, these loci only partially explain …

Immunotherapy is leading a paradigm shift in the treatment of various diseases, including
tumors, auto‐immune diseases, and infectious diseases. However, the limited response rate …

The accumulation of DNA and nuclear components in blood and their recognition by
autoantibodies play a central role in the pathophysiology of systemic lupus erythematosus …

Endogenous small molecules are metabolic regulators of cell function. Itaconate is a key
molecule that accumulates in cells when the Krebs cycle is disrupted. Itaconate is derived …

The prognosis in systemic lupus erythematosus (SLE) has improved due to better treatment
and care, but cardiovascular disease (CVD) still remains an important clinical problem, since …